Landec Corporation (DE) (LNDC) Peer Comparison
$7.00
$-0.14
(-1.96%)
As on 13-Jan-2023 09:30EDT
Market cap
$259 Mln
Revenue (TTM)
$278 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Edit
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
259 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
278 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-124.43 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-44.69 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-102.42 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 264.84 | -- | -- |
Price-To-Book |
2.70 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
185.79 | 77.65 | 401.86 | 4,411.00 | 50.04 |
|
Cost of Revenue
|
135.42 | 3.43 | 5.39 | 2,441.00 | 5.20 |
|
Gross Profit
|
50.37 | 74.21 | 396.47 | 1,970.00 | 44.84 |
|
Operating Expenses
|
53.97 | 586.42 | 283.84 | 1,586.00 | 224.64 |
|
Operating Profit (EBIT)
|
-41.29 | -512.20 | 112.63 | 384.00 | -179.80 |
|
Other Income
|
0.72 | 107.99 | 0.53 | -32.00 | -5.70 |
|
Profit before Tax
|
-52.12 | -484.65 | 116.19 | -72.00 | -187.13 |
|
Provision for Tax
|
-5.84 | 9.31 | 14.77 | 6.00 | 10.63 |
|
Profit after Tax (Net Income)
|
-97.43 | -481.18 | 101.42 | -78.00 | -187.13 |
|
Minority Interest
|
-- | 11.28 | -- | -- | -- |
|
Consolidated Profit
|
-97.24 | -481.18 | 101.29 | -78.00 | -187.13 |
Liabilities ($ Mln)
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
107.95 | -1,254.62 | 501.84 | 7,289.00 | 109.56 |
|
Minority Interest
|
-- | 11.28 | -- | -- | -- |
|
Non-Current Liabilities
|
107.98 | 1,746.53 | 9.10 | 6,500.00 | 125.36 |
|
Current Liabilities
|
79.23 | 121.43 | 72.49 | 1,702.00 | 96.56 |
|
Total Liabilities
|
295.16 | 623.04 | 583.43 | 15,491.00 | 331.48 |
Assets ($ Mln)
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
171.45 | 74.18 | 84.18 | 12,212.00 | 85.83 |
|
Current Assets
|
123.71 | 548.85 | 499.25 | 3,279.00 | 245.64 |
|
Total Assets
|
295.16 | 623.04 | 583.43 | 15,491.00 | 331.48 |
|
Total Debt*
|
153.19 | 1,723.56 | 1.14 | 5,836.00 | 94.68 |
|
Net Current Assets
|
44.58 | 387.45 | 426.76 | 1,577.00 | 149.08 |
Cashflow ($ Mln)
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-24.40 | -419.49 | 120.32 | 452.00 | -116.51 |
|
Cash Flow from Investing Activities
|
81.77 | 453.15 | -114.33 | -179.00 | -53.70 |
|
Cash from Financing Activities
|
-57.02 | -13.13 | -17.28 | -549.00 | 284.58 |
|
Net Cash Inflow / Outflow
|
0.35 | 20.52 | 1.43 | -276.00 | -97.40 |
Ratios
Profitability Ratios
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-28.43 | -72.65 | 23.07 | -0.58 | -138.83 |
|
ROE (%)
|
-62.71 | 45.29 | 23.11 | -1.05 | -298.97 |
|
ROA (%)
|
-24.42 | -58.83 | 20.14 | -0.49 | -89.27 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-52.24 | -259.21 | 25.24 | -1.78 | -373.99 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.66 | 0.11 | 0.10 | -0.07 | 4.67 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-198.27 | 14.46 | -9.86 | 83.85 | -38.68 |
|
EPS Growth (%)
|
-- | 0.17 | -0.05 | 0.84 | -0.21 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -2.37 | 23.30 | -76.53 | -17.91 |
|
Price / Book Value
|
-- | -0.91 | 4.71 | 0.82 | 30.59 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.23 | -6.01 | 16.71 | 13.22 | -18.50 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.42 | -1.37 | 0.00 | 0.80 | 0.86 |
|
Short term debt to equity ratio
|
0.42 | 0.00 | 0.00 | 0.05 | 0.00 |
|
Current Ratio
|
1.56 | 4.52 | 6.89 | 1.93 | 2.54 |
|
Quick Ratio
|
0.72 | 4.21 | 6.80 | 1.02 | 2.50 |
|
Interest Coverage
|
-4.95 | -5.03 | 31.67 | 0.72 | -24.51 |
Operating Efficiency Ratios
| Landec Corporation (DE) (LNDC) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.93 | 22.00 | 11.66 | 22.72 | 75.34 |
|
Asset Turnover
|
0.47 | 0.09 | 0.80 | 0.28 | 0.24 |
|
Receivable days
|
116.17 | 86.62 | 34.48 | 84.05 | 137.59 |
|
Inventory Days
|
184.10 | -1,646.87 | 376.03 | 217.64 | 151.78 |
|
Payable days
|
85.46 | 1,246.68 | 640.43 | 60.30 | 1,818.32 |
|
Cash Conversion Cycle
|
214.81 | -2,806.93 | -229.91 | 241.38 | -1,528.95 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
